



Pancreatic cancer trials open to recruitment – December 2025

This list includes trials targeted at pancreatic cancer alone and trials for many solid tumours which include pancreatic cancer. If you are a patient with pancreatic cancer and wish to discuss whether a clinical trial is right for you, please discuss with your treating Medical Oncologist.

NOTE: Trials listed are available for patients with pancreatic cancer to be referred for consideration. Several trials may have issues with slot availability or waitlists.

Descriptive stages of pancreatic cancer

Medical Term	What it means
Resectable	This is an early stage of pancreatic cancer where the cancer can still be removed by surgery
Unresectable or locally advanced	The pancreatic cancer has not spread around the body but unfortunately the cancer cannot be removed by surgery due to the tumour size, location, or involvement of surrounding structures
Metastatic	The pancreatic cancer has spread to other parts of the body



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>NeoFOL-R</u> Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicentre Randomized, controlled trial (NeoFOL-R) - Australian protocol	N/A	RESECTABLE Exclusion: Borderline resectable Locally advanced Previous treatment for pancreatic cancer	<u>mFOLFIRINOX chemotherapy</u> Arm A: Surgery then 12 cycles of chemotherapy Arm B: 6 cycles of chemotherapy before surgery followed by 6 of cycles after surgery	Epworth Health	EHJreissatiCentre@epworth.org.au
			 Further information: NeoFOL-R - Victorian Cancer Trials Link	Monash Health	gi.oncresearch@monashhealth.org
				Alfred Health	act-m@alfred.org.au
<u>DIRECT-InspIRE</u> Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy	N/A	UNRESECTABLE (Stage 3) Inclusion: 3 months of chemotherapy (FOLFIRINOX or Gemcitabine based – 1 line only)	<u>NanoKnife System for Irreversible Electroporation (IRE)</u> IRE is a technique using non-thermal energy to create permanent nanopores in the cell membrane in order to disrupt cellular homeostasis.	Peter MacCallum Cancer Centre	SurgicalResearchteam@petermac.org
			 Further information: DIRECT/InspIRE Australia - Victorian Cancer Trials Link	Alfred Health	charles.pilgrim@monash.edu
				Epworth Health	EHJreissatiCentre@epworth.org.au



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
AMG193 20230223 A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion AMG20230223	MTAP deletion	METASTATIC/LOCALLY ADVANCED (Second line)	<u>AMG 193</u> AMG 193 is a PMRT5 inhibitor which is administered orally.	Peter MacCallum Cancer Centre	PCCTU.MoncC@petermac.org
		Inclusion: Pancreatic cancer Homozygous MTAP-deletion	Further information: https://trials.cancervic.org.au/Details/vctlnct06360354	Austin Health	samantha.chakar@austin.org.au
		Exclusion: Prior MAT2A inhibitor or PRMT5 inhibitor		Epworth Health	EHjreissaticentre@epworth.org.au
AMPLICITY (AMP945-202) A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients	FAK	METASTATIC/LOCALLY ADVANCED (First line)	<u>Narmafotinib</u> Narmafotinib is an oral FAK inhibitor. Narmafotinib will be administered in combination with mFOLFIRINOX chemotherapy	Epworth	<u>EH-</u> PancreaticCentre@epworth.org.au
FMT Fecal Microbiota Transplantation to improve pain, symptom management and treatment efficacy in patients with pancreatic cancer	N/A	METASTATIC/LOCALLY ADVANCED (First line)	<u>Fecal Microbiota Transplantation</u> Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/fmt	Epworth	<u>EH-</u> PancreaticCentre@epworth.org.au



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
		allowed			
<u>LuMIERE</u> A Phase 1/2, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumour	FAP	METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Pancreatic ductal adenocarcinoma + other cancers <u>Combination cohort:</u> Chemotherapy naïve for advanced disease Exclusion: Active CNS disease	[177Lu]Lu-FAP-2286 [177Lu]Lu-FAP-2286 is a radiopharmaceutical that targets fibroblast activation protein (FAP). This treatment works by binding to the FAP to allow the targeted delivery of radiation directly to FAP-expressing cancer cells. [177Lu]Lu-FAP-2286 with chemotherapy Further information: https://trials.cancervic.org.au/details/vctlnct04939610	Alfred Hospital Peter MacCallum Cancer Centre	act-m@alfred.org.au PCCTU.MoncC@petermac.org
<u>PemOla</u> A phase II study combining pembrolizumab with olaparib in	dMMR/MS I-high or TMB > 4	METASTATIC/LOCALLY ADVANCED (Second line)	Pembrolizumab and Olaparib Pembrolizumab in anti-PD1 antibody	Monash Health	Gi.oncresearch@monashhealth.org



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/ Mb	mutations / Mb	Inclusion: Pancreatic cancer	Olaparib is a PARP inhibitor Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/pemola	Epworth	EH-PancreaticCentre@epworth.org.au
Porcupine P2EA An open-label study to assess the preliminary efficacy and safety of RXC004, (Zamaporvint), in patients with advanced pancreatic cancer who have progressed following therapy with current standard of care.	Porcupine	METASTATIC/LOCALLY ADVANCED (Second line) Inclusion: Progression on first line treatment for incurable disease Mandatory biopsy at enrolment	Zamaporvint Zamaporvint is an oral porcupine inhibitor. Treatment will be administered with denosumab Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/porcupine-p2ea	Epworth	EH-PancreaticCentre@epworth.org.au
GSK5764227/223675 A Phase1b/2, Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors	B7-H3	METASTATIC/LOCALLY ADVANCED (Second line) Inclusion: Pancreatic cohort (recently open)	GSK5764227 GSK5764227 is a B7H3 monoclonal antibody. Further information: https://trials.cancervic.org.au/Details/vctl_nct06885034	Austin Health	samantha.chakar@austin.org.au
PAUF-I A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability,	PAUF	METASTATIC/LOCALLY ADVANCED (Second line +) Inclusion:	PPB1510 PPB1510 is an IgG1 monoclonal antibody (mAb) that targets and neutralises PAUF.	Monash Health	earlyphase.oncresearch@monashhealth.org



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer		Received at least 1 line of chemotherapy and progressed	Further information: https://trials.cancervic.org.au/Details/vctlnct05141149		
<u>INCB161734</u> A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	KRAS G12D	ADVANCED OR METASATIC SOLID CANCERS (Second line +) Inclusion: Second line and beyond	<u>INCB161734</u> INCB161734 in a KRAS G12D inhibitor Further information: https://trials.cancervic.org.au/Details/vctlnct06179160	Alfred Health	act-m@alfred.org.au
<u>AP601</u> A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors	CD73 + CD137	ADVANCED OR METASATIC SOLID CANCERS (Second line +) Inclusion: Pancreatic ductal adenocarcinoma	<u>AP601</u> AP601 is a bispecific antibody that targets and inhibits CD73 on tumour cells and activates CD137 on T cells. AP601 is delivered as an infusion. Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/ap601	Epworth	EH-PancreaticCentre@epworth.org.au
<u>AMG 410</u> A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or	KRAS	ADVANCED OR METASATIC SOLID CANCERS (Exhausted standard of care) Inclusion: KRAS mutation or amplification Exhausted conventional treatment options Pancreatic cohort specified in	<u>AMG 410</u> AMG 410 is an oral pan-KRAS inhibitor and will be administered alone or in combination with pembrolizumab and panitumumab Further information: https://trials.cancervic.org.au/Details/vctlnct05141149	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Metastatic Solid Tumors		part 2.	ails/vctl_nct07094113		
ELK1004-101 A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors	HRR deficiency	METASTATIC/LOCALLY ADVANCED (Second line +) Inclusion: Suspected deleterious mutation of select HRR genes Exclusion: Prior PARP1 inhibitor	<u>EIK1004</u> EIK1004 is an oral PARP1 inhibitor and will be administered as monotherapy Further information: https://trials.cancervic.org.au/etails/vctl_nct06907043	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
ENG19 An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial)	EGFR	METASTATIC/LOCALLY ADVANCED (Third line +) Inclusion: Progressed on second line or treatment exhausted EGFR expression on local IHC or liquid biopsy **STUDY ON HOLD**	<u>E-EDV-D682/GC</u> E-EDV-D682/GC is a combination of a EnGelC Dream Vector (EDV) transporting the cytotoxic drug PNU-159682 to cells expressing EGFR and an EDV carrying alpha-galactosylceramide (EDV-GC). Further information: https://trials.cancervic.org.au/etails/vctl_actrn12625000203459	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>ADCE-T02-001</u> First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	Tissue Factor (TF)	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available Exclusion: Active CNS disease	AMT-754 AMT-754 is a targeting tissue factor antibody-drug conjugate (ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted treatment directly into the cell. Further information: https://trials.cancervic.org.au/details/vctl_nct06597721	Cabrini	clinicaltrials@cabrini.com.au
				Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
<u>HM-EZHI</u> A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors	SWI/SNF Complex aberration (ARID1A SMARCA4 SMARCA2)	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: SW/SNF Complex aberration (ARID1A, SMARCA4, SMARCA2) Exclusion: Prior valemertostat or other EZH1/2 inhibitor use	HM97662 HM97662 is an oral medication (EZH1/2 dual inhibitor). Further information: https://trials.cancervic.org.au/details/feed-cta-trial541	Peninsula and Southeast Oncology	ag@paso.com.au
				Grampians Health (Ballarat)	clinicaltrials@gh.org.au
<u>BGB 58067</u> A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	MTAP loss	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: MTAP loss (pre-screening available) Exclusion: Prior treatment with PRMT5 or MAT2A inhibitor	BGB-58067 BGB-58067 is an MTA-Cooperative PRMT5 inhibitor. Further information: NCT06589596 - Victorian Cancer Trials Link	Monash Health <i>(Note: Austin Health is only recruiting GBM)</i>	earlyphase.oncresearch@monashhealth.org



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>BGB 53038</u> A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, As Monotherapy or in Combinations in Patients with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications	KRAS mutation or amplification (excluding KRAS G12R)	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Evidence of KRAS mutation or wild-type amplification Exclusion: KRAS G12R mutation Prior treatment with other RAS targeting treatment	BGB-53038 BGB-53038 is a pan-KRAS inhibitor. Further information: NCT06585488 - Victorian Cancer Trials Link	Monash Health Peter MacCallum Cancer Centre	earlyphase.oncresearch@monashhealth.org PCCTU.EDD@petermac.org
<u>YL211</u> YL211-INT-101-01: A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors	cMET	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: No further standard treatment options available	YL211 YL211 is a C-MET targeted antibody-drug conjugate (ADC) available for all tumour types for dose escalation where there is either a C-met aberration or where there is a biological rationale for C-met directed therapy. Further information: YL211-INT-101-01 - Victorian Cancer Trials Link	Monash Health	earlyphase.oncresearch@monashhealth.org
<u>MK-1084</u> A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and	KRAS G12C	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: KRAS G12C mutation	MK1084 MK1084 is an oral KRAS G12C inhibitor.	Monash Health	earlyphase.oncresearch@monashhealth.org



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors			Further information: MK-1084 - Victorian Cancer Trials Link		
PRIMROSE A Modular Phase I/Ia, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient	MTAP deficient	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: At least 1 prior line of treatment and exhausted treatment options Archival or baseline tumour sample for MTAP testing Exclusion: Prior PRMT5 inhibitor	AZD3470 AZD3470 is a novel, potent and selective second-generation PRT5 inhibitor. Further information: PRIMROSE - Victorian Cancer Trials Link	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
CS5001 A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination with Systemic Therapies in Patients with Advanced Solid Tumors and Lymphomas.	ROR1	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Progression on at least 1 prior line of systemic therapy ECOG 0-1	CS5001 CS5001 is an antibody drug conjugate targeting ROR1 Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/cs5001	Epworth	connie.barlas@epworth.org.au or EH-PancreaticCentre@epworth.org.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
MarkV A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors	VISTA	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Progressed on available prior lines of therapy Progressed on PD-1 or PD-L1 inhibitor immunotherapy Exclusion: Prior anti-VISTA therapy	PMC-309 PMC-309 is an anti-VISTA monoclonal antibody PMC-309 will be administered alone or in combination with pembrolizumab Further information: https://trials.cancervic.org.au/Details/vctl_nct05957081	Grampians Health (Ballarat)	clinicaltrials@gh.org.au
				Cabrini	clinicaltrials@cabrini.com.au
AT-0174-001 A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	IDO1/TDO2	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Progressed on available prior lines of therapy	AT-0174 AT-0174 is a novel dual inhibitor of IDO1/TDO2 Further information: https://trials.cancervic.org.au/Details/vctl_actrn12623000956606	Grampians Health (Ballarat)	clinicaltrials@gh.org.au
				St Vincent's Hospital Melbourne	OncologyTrialCoordinators@svha.org.au
AKTive-001 A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation	AKT E17K mutation	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted standard of care therapies Exclusion: Prior mTOR or PI3K inhibitors Presence of KRAS, NRAS, HRAS or BRAF genomic alterations	ALTA2618 ALTA2618 is an oral AKT E17K inhibitor Further information: https://trials.cancervic.org.au/Details/vctl_nct06533059	Cabrini	clinicaltrials@cabrini.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>AMT-676-01</u> First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	CDH17	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second or later line therapy	<u>AMT-676</u> AMT-676 is an anti-CDH17 antibody drug conjugate. Further information: https://trials.cancervic.org.au/Details/vctI_nct06400485	Cabrini	clinicaltrials@cabrini.com.au
<u>D3S-001-100</u> A Phase 1, Open Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation	KRAS G12C	ADVANCED OR METASATIC SOLID CANCERS Inclusion: KRAS G12C mutation *Note pancreatic specific cohort has closed. Pantumour cohort remains open with limited slots	<u>D3S 001</u> D3S 001 is a KRAS G12C inhibitor Further information: https://trials.cancervic.org.au/Details/feed-cta-trial449	Cabrini Peter MacCallum Cancer Centre	clinicaltrials@cabrini.com.au PCCTU.EDD@petermac.org
<u>S095035</u> A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP	MAT2A MTAP	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Homozygous deletion of MTAP Second line and beyond	<u>S095035</u> S095035 is an oral MAT2A inhibitor. Further information: https://trials.cancervic.org.au/Details/vctI_nct06188702	Alfred Health	act-m@alfred.org.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
KEYNOTE-F49 A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose-escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors	LILRB1 LILRB2 KIR3DL1 PD-1	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second or later line	<u>IOS-1002 +/- Pembrolizumab</u> IOS-1002 binds to LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 receptors on innate and adaptive immune cells that suppress immune responses when activated. Pembrolizumab in anti-PD1 antibody. Further information: https://trials.cancervic.org.au/details/feed-cta-trial528	Bendigo Health Austin Health	cancerresearch@bendigohealth.org.au samantha.chakar@austin.org.au
GDC-7035 A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation	KRAS G12D	ADVANCED OR METASATIC SOLID CANCERS Inclusion: KRAS G12D mutation	<u>GDC-7035</u> GDC-7035 is a KRAS G12D inhibitor. Treatment will be monotherapy or in combination with other anti-cancer treatments. Further information: https://trials.cancervic.org.au/details/vctl_nct06619587	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
RO7566802 A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and	$\alpha\beta\delta$ integrin	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second or later line	<u>RO7566802</u> RO7566802 is a $\alpha\beta\delta$ integrin inhibitor delivered intravenously. Further information: https://trials.cancervic.org.au/details/ro7566802	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors			ails/vctl_nct06031441		
<u>MK-6837-001</u> A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors	TROP2	ADVANCED OR METASATIC SOLID CANCERS Exclusion: Uncontrolled HIV, Hepatitis B or C	<u>MK-6837 +/- pembrolizumab</u> MK-6837 is a TROP2-MMAE antibody-drug conjugate delivered as monotherapy or in combination with PD-1 inhibitor pembrolizumab. Further information: https://trials.cancervic.org.au/Details/vctl_nct06460961	Alfred Health	act-m@alfred.org.au
<u>BG-C477</u> A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors	CEACAM5	ADVANCED OR METASATIC SOLID CANCERS Inclusion: CEA >5	<u>BG-C477</u> BG-C477 is an antibody-drug conjugate targeting CEACAM5. BG-C477 will be delivered as monotherapy or in combination with capecitabine and bevacizumab. Further information: https://trials.cancervic.org.au/Details/vctl_nct06596473	Alfred Health	act-m@alfred.org.au
<u>BP44474</u> A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-	dMMR/ MSI-H	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Progressed on at least one prior line of therapy in the advanced	<u>RO7589831</u> RO7589831 is an orally administered WRN inhibitor Further information:	Alfred Health	act-m@alfred.org.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)		setting Tumour known to be d-MMR or MSI-H	https://trials.cancervic.org.au/details/vctl_nct06004245		
AMT-562-01 First-in-Human, Phase 1 Study of AMT-562, an Anti HER3 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	HER3	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second line and beyond	AMT-562 AMT-562 is a novel HER3 targeting antibody drug conjugate. Further information: https://trials.cancervic.org.au/details/vctl_nct06199908	Cabrini	clinicaltrials@cabrini.com.au
IKSUDA A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors	HER2	ADVANCED OR METASATIC SOLID CANCERS Inclusion: HER2 IHC 1-3+ HER2 ISH negative and positive	IKS014 IKS014 is a HER2 targeting antibody drug conjugate. Further information: https://trials.cancervic.org.au/details/vctl_nct05872295	Peninsula and Southeast Oncology	ag@paso.com.au
LOXO-RAS-200001 A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors	KRAS G12C	ADVANCED OR METASATIC SOLID CANCERS Inclusion: KRAS G12C mutation	LY3537982 LY3537982 is a KRAS G12C inhibitor and will be administered as monotherapy or in combination with other systemic anticancer medications.	Peninsula and Southeast Oncology	ag@paso.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
			Further information: https://trials.cancervic.org.au/details/vctl_nct04956640		
<u>Stingray SR-8541A-001</u> Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy in Subjects With Advanced/Metastatic Solid Tumors	ENPP1	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	SR-8541A SR-8541A is an ENPP1 inhibitor. Further information: https://trials.cancervic.org.au/details/vctl_nct06063681	Peninsula and Southeast Oncology	ag@paso.com.au
<u>BAY3498264</u> Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors	SOS1 KRAS	ADVANCED OR METASATIC SOLID CANCERS Inclusion: KRAS G12C mutation	BAY3498264 BAY3498264 is a SOS1 inhibitor. Treatment will be in combination with sotorasib. Further information: https://trials.cancervic.org.au/details/vctl_nct06659341	Peninsula and Southeast Oncology	ag@paso.com.au
<u>AK138D1</u> A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors	HER3	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	Patritumab Deruxtecan Patritumab Deruxtecan an anti-HER3 Antibody drug conjugate Further information: https://trials.cancervic.org.au/details/vctl_nct06730386	Peninsula and Southeast Oncology	ag@paso.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>DT-7012-CLI-001</u> Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL)	CCR8	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second or later line	<u>DT-7012</u> DT-7012 is an anti-CCR8 antibody. Further information: <u>https://clinicaltrials.gov/study/NC06819735</u>	Peninsula and Southeast Oncology	<u>ag@paso.com.au</u>
<u>SNV4818</u> A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors	PIK3CA	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Activating PIK3CA mutation Exhausted conventional treatment <i>Note: Pantumour for dose escalation cohorts</i>	<u>SNV4818</u> SNV4818 is an oral PI3K α inhibitor. SNV4818 will be delivered with or without fulvestrant Further information: <u>NCT06736704 - Victorian Cancer</u>	Monash Health	<u>earlyphase.oncresearch@monashhealth.org</u>
<u>BM230</u> A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors	HER2	ADVANCED OR METASATIC SOLID CANCERS Inclusion: HER2 1+ expression	<u>BM230</u> BM230 is delivered subcutaneously each week for 3 weeks followed by fortnightly administration Further information: <u>BM230 - Victorian Cancer Trials</u>	Monash Health	<u>earlyphase.oncresearch@monashhealth.org</u>
<u>BT317</u> A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in		ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>BT317</u> BT317 is administered intravenously Further information: <u>NCT06750185 - Victorian Cancer</u>	Monash Health	<u>earlyphase.oncresearch@monashhealth.org</u>



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Patients with Advanced Solid Tumors			Trials Link		
<u>OZ-001-101</u> A Phase 1, Open-label, First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumours with a Focus on Triple Negative Breast Cancer	STAT3	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted conventional treatment Confirmed accepting PDAC for phase 1a	<u>OZ-001</u> OZ-001 is a small molecule dual inhibitor of the STAT3 and T-type calcium channels Further information: https://trials.cancervic.org.au/details/vctl_actrn12625000163404	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
<u>INI-4001-101</u> An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients with Advanced Solid Tumours	TLR7/8	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted conventional treatment Pre-screening component (review of medical history) *Minimal slots available	<u>INI-4001</u> INI-4001 is TLR7/8 agonist. Further information: https://trials.cancervic.org.au/details/vctl_nct06302426	Cabrini	clinicaltrials@cabrini.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>LM350-01-10</u> A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients with Advanced Solid Tumors	CDH17	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>LM350</u> LM350 is a CDH17 targeted antibody drug conjugate Further information: https://clinicaltrials.gov/study/NC07112222?aggFilters=status:not	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
<u>RO7673396</u> A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)	RAS	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted conventional treatment Confirmed presence of RAS mutation	<u>RO7673396</u> RO7673396 is an oral RAS inhibitor Further information: https://trials.cancervic.org.au/details/vctlnct06884618	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
<u>AK146D1-102</u> A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of AK146D1 for Injection, an Anti-Trop2/Nectin4 Bispecific Antibody-drug Conjugate, in Patients With Advanced Solid Tumors	TROP2 NECTIN4	ADVANCED OR METASATIC SOLID CANCERS Exclusion: Prior TROP2 or NECTIN4 targeting treatments Prior topoisomerase 1 inhibitor treatment	<u>AK146D1</u> AK146D1 is a an anti-TROP2/NECTIN4 bispecific antibody drug conjugate Further information: https://trials.cancervic.org.au/details/vctlnct06929663	Austin Health	samantha.chakar@austin.org.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>IDOV-Immune for Advanced Solid Tumors</u> A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors	N/A	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>IDOV-Immune</u> IDOV-immune is an oncolytic virus therapy administered intravenously. Patients will receive one dose of therapy. Further information: https://trials.cancervic.org.au/Details/vctl_nct06910657?utm_source=ccv-website&utm_medium=website&utm_campaign=api	Alfred Health	act-m@alfred.org.au



SUPPORTIVE CARE TRIALS FOR PATIENTS WITH PANCREATIC CANCER					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>DINE-PC</u> Dietetics Intervention and Nutritional Evaluation in Pancreatic Cancer Care (DINE-PC)	N/A	ALL STAGES OF PANCREATIC CANCER	<u>Dietetics counselling</u> Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/dine-pc	Epworth Victoria	<u>EH-</u> PancreaticCentre@epworth.org.au
<u>SuperQol:</u> Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy and symptom control, on quality of life in patients with pancreatic cancer: a randomised controlled trial	N/A	ALL STAGES OF PANCREATIC CANCER	<u>Dietician counselling/intervention</u> Patients will be randomised to receive usual care or intensive dietetics intervention Further intervention: https://trials.cancervic.org.au/details/vct1_actrn12624000084583	Latrobe Regional Hospital Victoria	clinicaltrials@lrh.com.au

**Phase 1 Trials are offered in Victoria at the following locations:**

Study Site	Contact	Email	Phone
Alfred Hospital (Prahran VIC 3004)	Clinical Trial Team	moncACT1@alfredhealthconnect.onmicrosoft.com	TBA
Austin Hospital (Heidelberg VIC 3084)	Samantha Chakar	samantha.chakar@austin.org.au	03 9496 3088
Barwon Health (Geelong VIC 3220)	Karen Aitken	cstu.manager@barwonhealth.org.au	03 4215 2758
Cabrini Malvern (Malvern VIC 3144)	Rochelle Woods	rwoods@cabrini.com.au	95083437
Epworth Hospital (Richmond VIC 3121)	Clinical Research Coordinator	ehjreissaticecentre@epworth.org.au	0448 842 680 or 03 9426 8880
PASO Medical (Frankston VIC 3199)	Albert Goikman Clinical Trials Manager	ag@paso.com.au	03 91131307
Monash Health (Clayton VIC 3168)	Early Phase Research Study Coordinator	earlyphase.oncresearch@monashhealth.org	0474 769 510
Peter MacCallum Cancer Centre (Parkville VIC 3052)	Enquiries Line Coordinator	clinicaltrials.enquiries@petermac.org	03 8559 7456 (9am-2pm, Mon-Fri)
St Vincent's Hospital (Fitzroy VIC 3065)	Nadia Ranieri	oncology.research@svha.org.au	03 9231 3167
Western Health (St Albans VIC 3021)	Heike Raunow	CancerClinicalTrials@wh.org.au	03 83959136 or 0434915739

For patients not eligible for any of the above trials, and who have pancreatic cancer that has progressed, are intolerant or are ineligible for standard of care treatments, please consider a phase 1 trial. Clinicians can email or phone the contact listed with any enquiries. Patients, please contact your treating Medical Oncologist if you wish to discuss phase 1 trials.



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>Porcupine P2EA</u> An open-label study to assess the preliminary efficacy and safety of RXC004, (Zamaporvint), in patients with advanced pancreatic cancer who have progressed following therapy with current standard of care.	Porcupine	PANCREATIC CANCER - METASTATIC/LOCALLY ADVANCED (Second line) Inclusion: Progression on first line treatment for incurable disease Mandatory biopsy at enrolment	Zamaporvint Zamaporvint is an oral porcupine inhibitor. Treatment will be administered with denosumab Further information: https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12624000588594p	Gold Coast University Hospital	Susan.Caird@health.qld.gov.au
<u>CA240-0030</u> A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	MTAP deletion	PANCREATIC CANCER - METASTATIC/LOCALLY ADVANCED Inclusion: Untreated advanced pancreatic cancer Homozygous MTAP deletion	<u>BMS-986504</u> Patients will receive gemcitabine and nab-paclitaxel combined with BMS-986504 (a novel PRMT5 inhibitor) or placebo. Further information: https://www.clinicaltrials.gov/study/NCT07076121	Royal Brisbane & Women's Hospital Genesis Care Norths Shore (NSW)	amy.ives@health.qld.gov.au admin.northshore@genesiscare.com



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>AMG193 20230223</u> A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion <u>AMG20230223</u>	MTAP deletion	PANCREATIC CANCER - METASTATIC/LOCALLY ADVANCED Inclusion: Pancreatic cancer Homozygous MTAP-deletion Exclusion: Prior MAT2A inhibitor or PRMT5 inhibitor	<u>AMG 193</u> AMG 193 is a PMRT5 inhibitor which is administered orally. AMG 193 will be administered with chemotherapy. Further information: <u>https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13988</u>	Genesis Care Norths Shore (NSW) Chris O'Brien Lifehouse	<u>admin.northshore@genesiscare.com</u> <u>jasmine.sell@lh.org.au</u>
<u>AMPLICITY (AMP945-202)</u> A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients	FAK	PANCREATIC CANCER - METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Treatment naïve for metastatic disease	<u>Narmafotinib</u> Narmafotinib is an oral FAK inhibitor. Narmafotinib will be administered in combination with mFOLFIRINOX chemotherapy Further information: <u>AMPLICITY Trial</u>	Genesis Care Norths Shore (NSW)	<u>admin.northshore@genesiscare.com</u>
<u>MountainTAP-30</u> A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo	MTAP	PANCREATIC CANCER - METASTATIC/LOCALLY ADVANCED (First line) Inclusion	<u>BMS-986504</u> BMS-986504 is a selective MTA-cooperative PRMT5 inhibitor. Patients receive	St John Of God Murdoch Hospital	<u>Mel.Hernandez@sjog.org.au</u>



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion		First line treatment of metastatic pancreatic cancer Homozygous MTAP deletion	gemcitabine and nab-paclitaxel with or without BMS-986504 Further information: https://cancertrialswa.zepli.com.au/clinical-trials/90123		
<u>CA233-0000/</u> <u>BMS-986484</u> A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors	CD40/FAP	ADVANCED OR METASTATIC SOLID CANCERS Exclusion: History of ILD	<u>BMS-986484</u> BMS-986484 (a CD40/FAP bispecific agonist) is delivered as monotherapy or in combination with nivolumab Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14232	St Vincent's Hospital Darlinghurst (NSW)	svhs.research@svha.org.au
<u>ALKOVE-1</u> A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-to655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-to1)	ALK	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: ALK rearrangement or activating ALK mutation	<u>NVL655</u> NVL655 (neladalkib) is an oral selective ALK inhibitor. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13595	Royal North Shore Hospital NSW	PI: malinda.itchins@sydney.edu.au Trial coordinator: shirley.liang@health.nsw.gov.au



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>AT-0174-001</u> A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	IDO1/TDO2	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Progressed on available prior lines of therapy	AT-0174 AT-0174 is a novel dual inhibitor of IDO1/TDO2 Further information: https://www.anzctr.org.au/Trial	Royal North Shore Hospital (NSW)	PI: helen.wheeler@health.nsw.gov.au Trial Coordinator: wengqiong.yu@health.nsw.gov.au
<u>BGB-58067</u> A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	MTAP deficiency	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Any treatment line	BGB-58067 BGB-58067 is a PMRT5 inhibitor Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14130	Blacktown Cancer & Haematology Centre (NSW)	William.dAvigdor@health.nsw.gov.au
<u>GeneScreen 5FU</u> DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Cancer	DPYD	SOLID CANCERS – ALL STAGES Inclusion: Intention to treat with Fluoropyrimidine (FP) containing chemotherapy Exclusion: Prior FP containing chemotherapy prior to study entry.	DPYD genotyping Pre-emptive DPYD genotyping prior to commencing Fluoropyrimidine chemotherapy Further information: ANZCTR - Registration	Lake Macquarie Private Hospital (NSW) Fiona Stanley Hospital (WA)	ClinicalTrialsUnit.LMP@ramsayhealth.com.au audrey.margery-Muir@health.wa.gov.au



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>INCB161734</u> A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	KRAS G12D	ADVANCED OR METASATIC SOLID CANCERS (Second line +) Inclusion: Second line and beyond ***Long waitlist***	<u>INCB161734</u> INCB161734 in a KRAS G12D inhibitor Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14020	St Vincent's Hospital Darlinghurst (NSW)	robert.kent@svha.org.au
<u>BAY3713372</u> A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2 nd generation PRMT5 inhibitor in participants with MTAP deleted solid tumors	MTAP loss	ADVANCED OR METASATIC SOLID CANCERS Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion	<u>BAY 3713372</u> BAY 3713372 is a novel 2 nd generation PRMT5 inhibitor. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14234	Chris O'Brien Lifehouse	teresa.nicholls@lh.org.au
<u>BNT326-01</u> A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors	HER3	ADVANCED OR METASATIC SOLID CANCERS Inclusion Second or third line	<u>BNT326</u> BNT326 is a HER3 targeted ADC with a topoisomerase I inhibitor. Further information: https://cancertrialswa.zepli.com.au/clinical-trials/80123	One Clinical Research, Hollywood Medical Centre, Nedlands WA	scott.mcgregor@oneclinicalresearch.com.au



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
KANDLEIT-014 A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLEIT-014)	KRAS G12C	ADVANCED OR METASTATIC SOLID CANCERS Inclusion Progression on standard of care therapy	<u>MK-1084</u> MK-1084 is an oral KRAS G12C inhibitor. Patients will be treated alone or in combination with cetuximab. Further information: https://clinicaltrials.gov/study/NCT07209111	Prince of Wales Hospital, NSW	<u>SESLHD-POW-</u> CTRreferrals@health.nsw.gov.au

PANCREATIC CANCER TRIALS IN SINGAPORE

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
LDOXIRI-PDAC-01 A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients.	NA	METASTATIC/LOCALLY ADVANCED Inclusion: Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma	<u>Metronomic capecitabine, oxaliplatin and UGT1A1 genotype directed irinotecan</u> Further information: https://clinicaltrials.gov/study/NC05929885?term=NCT05929885&rank=1b	National Cancer Centre Singapore	honey.shwe.sin@nccs.com.sg



PANCREATIC CANCER TRIALS IN SINGAPORE					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2 nd generation PRMT5 inhibitor in participants with MTAP deleted solid tumors	MTAP loss	ADVANCED OR METASTATIC SOLID CANCERS Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion	<u>BAY 3713372</u> BAY 3713372 is a novel 2 nd generation PRMT5 inhibitor. Further information: https://clinicaltrials.gov/study/NCT06914128	National Cancer Centre Singapore	Wang.jue.lynn@nccs.com.sg
A phase I/II Dose-Escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in patients with advanced solid tumors with a KRAS G12D mutation	KRAS G12D	METASTATIC/LOCALLY ADVANCED Inclusion: Systemic Treatment refractory KRAS G12D pancreatic adenocarcinoma	<u>GDC-7035</u> GDC-7035 is a KRAS G12D inhibitor	National Cancer Centre Singapore	Ye.xin@nccs.com.sg
<u>PAUF-I</u> A first in human phase I/2A, multicentre, open label study of evaluating the safety, tolerability, pharmacokinetics, and efficacy of PBP1510 in patients with advanced/metastatic pancreatic cancer	PAUF	METASTATIC/LOCALLY ADVANCED Inclusion: Systemic Treatment exposed pancreatic adenocarcinoma	<u>PBP 1510</u> PBP 1510 is an anti-PAUF antibody Further information: https://clinicaltrials.gov/study/NCT05141149	National Cancer Centre Singapore	Goh.mui.leng@singhealth.com.sg



PANCREATIC CANCER PREVENTION					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
APRISE Assess the effectiveness of the Australian Pancreatic High-Risk Screening Program in identifying early-stage pancreatic cancer among high-risk individuals due to familial or genetic risk factors	NA	FAMILY HISTORY OF PANCREATIC CANCER Inclusion: High risk features for pancreatic cancer development	<u>Screening</u> Screening with endoscopic ultrasound or MRI for a period of 10 years Further information: https://trials.cancervic.org.au/details/vctl_actrn12624000421538	Epworth Health	EHJreissatiCentre@epworth.org.au